37 signatories have called on Congress to pass the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. This coalition represents a broad-based and diverse cross-section of stakeholders – including providers and payers, physicians and consumers, businesses and unions – all of whom have come together in strong support of this important legislation. Read More
"While we are very excited about the potential for CAR-T therapies to save lives, Novartis’ pricing decision disappointingly pushes an unsustainable trend even closer to the breaking point." Read More
CSRxP Calls for Action on CREATES Act The Campaign for Sustainable Rx Pricing… Read More
CSRxP spokesman Will Holley releases statement following House passage of FDA user fee legislation. Read More
CSRxP Releases Powerful Testimonial: “Debbie’s Story” The… Read More
“The Right” highlights examples of Big Pharma’s price-gouging tactics, such as Miacalcin’s 3,200% price hike, Daraprim’s 5,000% price hike, and doxycycline’s 9,000% price increase in just six months. These price hikes are part of a longstanding pattern that show no sign of slowing down - in fact, a recent report showed that there were more price hikes in the first quarter of 2017 than there were in the first quarter of 2016. Read More
It's time for Big Pharma to get their priorities straight: American's deserve open and honest prescription drug pricing. Read More
“The people served by ACAP’s members are among the most vulnerable to the out-of-control prices of prescription medications and they have first-hand experience with the effect that Big Pharma’s pricing policies have on real people every day,” said John Rother, Executive Director of CSRxP. Read More
“If PhRMA’s members are serious about their commitment to affordability, we invite them to join us in supporting common-sense, bipartisan reforms like the CREATES and FAST Generics Acts that address equally-egregious, though less-publicized, anticompetitive abuses as the ones that prompted this change in policy.” Read More
“Transparency is one of the keys to market-based reforms that will lead to lower prices and ensure that taxpayers receive a real return on their investment." Read More
CSRxP has launched a national campaign as part of a multi-million-dollar effort to hold Big Pharma accountable for their out-of-control prescription drug prices. Because Big Pharma blocks competition to maintain monopolies on medicines, they can set any price they want. Read More
“Big Pharma’s longstanding pattern of utilizing the REMS process to forestall generic and biosimilar medications from reaching patients is an anticompetitive and cynical abuse of an important tool for patient safety." Read More